Market Overview

Quanterix' Ultra-Sensitive Technology Creates Breakthroughs in Brain Health of Military and Veterans


New research advances the diagnosis of concussions and PTSD for those
in the line of duty

(NASDAQ:QTRX), a company digitizing biomarker analysis
with the goal of advancing the science of precision health, today
announced that researchers have uncovered novel links between several
blood-based biomarkers and the diagnosis of brain injuries and chronic
neuropsychological symptoms in military personnel and veterans, using
its flagship Simoa
. With unprecedented levels of sensitivity, Simoa is
giving researchers the ability to achieve never-before-seen insights
into the diagnosis of brain injuries and the relationship between these
conditions and PTSD in our military.

According to the Defense
and Veterans Brain Injury Center
, nearly 800,000 veterans have been
diagnosed with traumatic brain injuries (TBIs) since 2000 and more than
80 percent are considered to be mild (mTBI). Previously, researchers
lacked the sensitivity needed to examine mTBIs, which often do not
present symptoms and frequently go undiagnosed, potentially leading to
neurological complications later in life.

A recent study
published in Brain Injury showed that elevated levels of exosomal
tau, amyloid-beta (Aβ42) and IL-10, now measurable with the Simoa
technology in blood, are associated with mTBIs and chronic symptoms in
military personnel. The findings suggest that measuring these exosomal
markers may provide a way to detect mTBIs prior to the onset of
symptoms, and therefore allow a wider range of potential treatments. The
study also advances our understanding of the relationship between mTBIs
and PTSD, correlating inflammation of the brain following an mTBI with
progression of chronic PTSD symptoms.

"The health and safety of our military personnel and veterans are a top
concern. These men and women risk their lives to protect our country and
we owe it to them to fight just as hard to protect their health," said
Kevin Hrusovsky, CEO, President and Chairman of Quanterix and the
Founder of Powering Precision Health. "Our ability to finally see
concussions and other neurological injuries with a blood test means our
soldiers could soon benefit from the immediate diagnosis of even the
mildest concussions. Science-based evidence is essential to advancing
precision health, bringing us closer to preventing mental health
disorders such as PTSD, and widening our addressable market in
neurology, a therapeutic category with some of the most lethal diseases."

Another study
published in Brain Injury sought to examine plasma and exosomal
levels of tau, phosphorylated tau (p-tau), Aβ42 and Aβ40 in veterans
with historical mTBIs and chronic neuropsychological symptoms. The
findings indicate that elevations of exosomal tau and exosomal p-tau
significantly correlate with post-traumatic and post-concussive symptoms
in veterans with repetitive mTBIs (rTBIs). The findings also suggest
that blood-based exosomes may provide another reliable biomarker source
for remote mTBIs and that rTBIs may contribute to chronic
neuropsychological symptoms.

"These findings are pivotal to understanding biomarker pathology with
relation to mTBIs and post-concussive symptoms, which has never before
been possible to this degree," said Dr. Jessica Gill, Senior
Investigator in the Tissue Injury Branch, National Institutes of Health
and one of the leading authors of both studies. "Furthermore our ability
to see a link between PTSD and mTBIs indicates that we could soon be
able to diagnose the disease through a non-invasive blood test, which
would be incredibly groundbreaking."

About Quanterix
Quanterix is a company that's digitizing
biomarker analysis with the goal of advancing the science of precision
health. The company's digital health solution, Simoa, has the potential
to change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from health to
disease. Quanterix' technology is designed to enable much earlier
disease detection, better prognoses and enhanced treatment methods to
improve the quality of life and longevity of the population for
generations to come. The technology is currently being used for research
applications in several therapeutic areas, including oncology,
neurology, cardiology, inflammation and infectious disease. The company
was established in 2007 and is located in Lexington, Massachusetts. For
additional Information, please visit

Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as "may," "will," "expect,"
"plan," "anticipate," "estimate," "intend" and similar expressions (as
well as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on Quanterix'
expectations and assumptions as of the date of this press release. Each
of these forward-looking statements involves risks and uncertainties.
Factors that may cause Quanterix' actual results to differ from those
expressed or implied in the forward-looking statements in this press
release are discussed in Quanterix' filings with the U.S. Securities and
Exchange Commission, including the "Risk Factors" sections contained
therein. Except as required by law, Quanterix assumes no obligation to
update any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes available.

View Comments and Join the Discussion!